glp 1 drug class What to Make of the GLP-1 Coverage and Cost Landscape GLP-1 Agonist-Induced Delayed Gastric Emptying

doi: 10.1056/NEJMoa1912388

This leads to the release of insulin into the bloodstream

Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: a disproportionality analysis

The Triple Agonist Mechanism Explained Retatrutide is a single-molecule triple agonist that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon

While it is complicated to make any long-term projections, we could be in a situation where about 10% of the population uses them by 2030

Misclassification of unexposed also has to be taken into account due to possible parallel import of GLP-1 RA and thus not registered as a prescription in the national registry